Ventritex evaluating technologies for atrial tachyarrhythmia treatment.
This article was originally published in The Gray Sheet
Executive Summary
VENTRITEX EYEING ATRIAL TACHYARRHYTHMIA MARKET, company President and CEO Frank Fischer told investors Oct. 17 at the UBS Securities life sciences conference in New York City. The Sunnyvale, California-based manufacturer of implantable cardioverter defibrillators used to treat ventricular tachyarrhythmias is "very interested" in pursuing technologies that could treat atrial tachyarrhythmias, Fisher said. "The very same physician that sees patients with ventricular tachyarrhythmias, most or a good portion of their business is in detecting or treating atrial tachyarrhythmias as well."
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.